Additionally, we have developed novel DDX3X PROTAC degraders and compared their anti-tumor efficiency with RK-33, showcasing their great potential and advantages in targeting DDX3X for lung cancer therapeutics. The gene discussed is DDX3X; the disease is lung carcinoma.